Skip to main content

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Immune profiling to guide host-directed interventions to cure HBV infections

IP: Maria Buti Ferret
Collaborators: Tamara Del Rio Higueras, Mª Eulàlia Molinas Guilera, Amaia Latasa Arrazubi, Judit Vico Romero, Alejandro López Targa, Maria del Mar Riveiro Barciela
Funding agency: EUROPEAN COMMISSION
Funding: 211443.8
Reference: IP-CURE-B_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

Estudio prospectivo para identificar nuevos marcadores plasmáticos de replicación viral en pacientes con hepatitis crónica por virus de la hepatitis B (VHB) y/o Delta (VHD)

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela, Adriana Palom Agusti, Maria Francesca Cortese
Funding agency: Instituto de Salud Carlos III
Funding: 224757.5
Reference: PI17/02233
Duration: 01/01/2018 - 31/12/2021

Carotid atherosclerosis and chronic hepatitis B: role of persistent viral suppression and immunemediated response. A prospective study.

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 49005
Reference: GLD16_00057
Duration: 14/12/2016 - 13/12/2018

Búsqueda de posibles dianas terapéuticas en la región del gen x del virus de la hepatitis B en base al estudio de conservación de dicha región mediante secuenciación masiva.

IP: -
Collaborators: Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria del Pilar Reimundo Diaz-Fierros, Andrea Caballero Garralda
Funding agency: Instituto de Salud Carlos III
Funding: 110715
Reference: PI15/00856
Duration: 01/01/2016 - 30/06/2019

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Julia Salvador Lodosa

Julia Salvador Lodosa

Read more
Marina Hortola Bufi

Marina Hortola Bufi

Read more
Adrian Nuñez Cardoso

Adrian Nuñez Cardoso

Research technician
Rheumatology
Read more
Santiago Rodríguez-Tubío Dapena

Santiago Rodríguez-Tubío Dapena

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.